Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBTH17 Cells May Serve as Biomarker in Metastatic Melanoma. By Morgan Bayer. September 28th 2024. TH17 cells may be a potential biomarker to predict the risk of immune-related adverse events in patients with metastatic melanoma receiving the combination therapy of nivolumab, ipilimumab, and tocilizumab.
Neoadjuvant/Adjuvant Durvalumab Scores FDA Approval in …
WEBAug 15, 2024 · The FDA approved durvalumab (Imfinzi) with platinum-containing chemotherapy in patients with resectable non–small cell lung cancer (NSCLC) without EGFR mutations or ALK rearrangements. This approval is supported by the phase 3 AEGEAN trial (NCT03800134). Durvalumab led to notable improvements in event-free survival (EFS) vs placebo.
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
WEBDec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...
FDA Accepts Cabozantinib Application in Advanced …
WEBAug 7, 2024 · Microscopic, photorealistic image of neuroendocrine tumor cells - Generated with Google Gemini AI. The FDA has accepted the filing of a supplemental new drug application (sNDA) of cabozantinib (Cabometyx) for the treatment of neuroendocrine tumors (NETs). A Prescription Drug User Fee Act (PDUFA) target …
The Potential of STING Agonists Is Explored in Cancer
WEBMar 30, 2022 · Stimulator of interferon genes (STING) is an endoplasmic protein that induces the production of proinflammatory cytokines and has become a target of interest to obtain or boost antitumor immune responses. 1 First-generation STING agonists are structurally unstable, which has driven development of compounds with greater stability and …
Addition of Pembro to Neoadjuvant Chemo Aids EFS in High-Risk …
WEBOct 20, 2023 · At 5 years, the EFS rate among patients treated with pembrolizumab plus chemotherapy was 81.3%, compared with 72.3% in the placebo arm, reducing the risk for recurrence, progression, complications, or death by 37% (HR, 0.63; 95% CI, 0.49-0.81). The median EFS was not reached in either group. “What's also …
Dostarlimab Plus SOC Chemo Meets Primary End Point in …
WEBDec 18, 2023 · Dostarlimab-gxly (Jemperli) in combination with standard-of-care chemotherapy followed by dostarlimab plus niraparib (Zejula) as maintenance therapy in adult patients with primary advanced or recurrent endometrial cancer showed statistically significant and clinically meaningful improvements in the primary end point of progression-free survival (PFS), according to planned analysis of part 2 of ...
Recent Approvals Signal a Bright Future for Myelodysplastic …
WEBDec 22, 2023 · Ivosidenib . In October 2023, ivosidenib (Tibsovo) was cleared by the FDA for the treatment of IDH1-mutated relapsed or refractory MDS, based on findings from the AG120-C-001 trial (NCT02074839).4 In the study, 18 adult patients with relapsed or refractory MDS with an IDH1 mutation received oral ivosidenib daily on a 28-day cycle. All responses in the trial were complete responses (CRs), and ...
High-Dose Radiation Plus Long-Term ADT Improves Survival in …
WEBJan 25, 2024 · Utilizing a higher dose of radiation therapy in combination with the long-term use of androgen deprivation therapy (ADT) improved survival outcomes after 10 years of follow-up in patients with high-risk prostate cancer, according to long-term results from the GETUG-AFU 18 trial (NCT00967863) presented at the 2024 ASCO Genitourinary Cancers ...
Maintenance Therapies in Metastatic Colorectal Cancer - Targeted …
WEBOct 4, 2021 · Treatment Sequencing in Metastatic Colorectal Cancer. Kanwal Raghav, MBBS, MD: Maintenance therapy is a fairly common method that we apply in colorectal cancer, partly because the response from chemotherapy is pretty good in first-line treatment. Most patients will benefit from chemotherapy initially, but at some point, toxicities become limiting.